Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR plus NSCLC

被引：1
|
作者：
Chen, Lanyi Nora [1 ]
Lee, Alexandria T. M. [2 ]
Nagasaka, Misako [1 ,2 ,3 ]
Ou, Sai-Hong Ignatius [2 ,3 ,4 ]
机构：
[1] Columbia Univ, Vagelos Coll Phys & Surg, Irving Med Ctr, Dept Med,Div Hematol Oncol, New York, NY USA
[2] Univ Calif Irvine, Sch Med, Orange, CA USA
[3] Chao Family Comprehens Canc Ctr, Orange, CA USA
[4] Univ Calif Irvine, Sch Med, Dept Med, Div Hematol & Oncol, 200 South Manchester Ave, Suite 400, Orange, CA 92868 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 03期
关键词：
CELL LUNG-CANCER;
D O I：
10.1016/j.jtho.2023.12.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：380 / 384
页数：5
相关论文
共 50 条
  • [1] Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Lim, Sun Min
    Lee, Jii Bum
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 376 - 379
  • [2] EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
    Moore, Sara
    Wheatley-Price, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1788 - 1792
  • [3] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie Pei Li
    Low, Yi Fen
    Lai, Gillianne
    Chan, Landon
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia
    Seet, Amanda Oon Lim
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren Wan-Teck
    Tan, Daniel Shao-Weng
    Mok, Tony S. K.
    Li, Molly Sc
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie P. L.
    Low, Yi Fen
    Lai, Gillianne G. Y.
    Chan, Landon L.
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia H.
    Seet, Amanda O. L.
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan -Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren W. T.
    Tan, Daniel S. W.
    Mok, Tony S. K.
    Li, Molly S. C.
    LUNG CANCER, 2024, 193
  • [5] COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib
    Sequist, L. V.
    Peled, N.
    Tufman, A.
    Servidio, L.
    Li, J.
    Taylor, R.
    Zhao, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1101 - S1101
  • [6] COMPEL: Chemotherapy with/without Osimertinib in Patients with EGFRm advanced NSCLC and Progression on first-line Osimertinib
    Tufman, Autoren A.
    Sequist, L.
    Peled, N.
    Servidio, L.
    Li, J.
    Taylor, R.
    Zhao, J.
    de Wit, M.
    PNEUMOLOGIE, 2023, 77 : S8 - S8
  • [7] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
    Ricciuti, Biagio
    Chiari, Rita
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
  • [8] Anti-EGFR Monoclonal Antibodies plus Chemotherapy in the First-Line Treatment of Advanced NSCLC: A Meta-Analysis
    Stock, Gustavo
    Aguiar, Pedro, Jr.
    Santoro, Ilka
    Tadokoro, Hakaru
    De Mello, Ramon
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S333 - S334
  • [9] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
    Liam, C. K.
    Kim, T. M.
    Yang, J-J.
    Huang, C.
    Voon, P-J.
    Tho, L. M.
    Zhou, Q.
    Wang, J.
    Hayashi, H.
    Tan, D. S. W.
    Danchaivijitr, P.
    Nguyen, V. N.
    Wong, K. H.
    Yang, J. C-H.
    Le, X.
    Ellers-Lenz, B.
    Karachaliou, N.
    Ghori, V.
    Berghoff, K.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
  • [10] First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation
    Yanjuan Xiong
    Lu Wang
    Weihong Zhang
    Yuan Meng
    Yang Wang
    Meng Shen
    Li Zhou
    Runmei Li
    Yingge Lv
    Shengguang Wang
    Xiubao Ren
    Liang Liu
    BMC Cancer, 24 (1)
12345